The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

There's new evidence the class of drugs that includes Ozempic may have health benefits that go beyond diabetes treatment and weight loss. A major new study suggests these drugs could help with dozens ...

Study shows diabetes drugs' potential beyond weight loss A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

A new study found people with type 2 diabetes who used drugs like Ozempic had a reduced risk of 42 health conditions or ...

New diet drugs are making it easier to lose weight. So does that mean we can stop exercising? Health experts say no. There is ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...